자폐스펙트럼장애 치료 시장 : 전략적 인사이트와 예측(2026-2035년)

The Global Autism Spectrum Disorder Treatment Landscape Report is set to reach USD 31.70 billion in 2035, growing at a CAGR of 7.1% from USD 17.04 billion in 2026

The global autism spectrum disorder (ASD) treatment market is experiencing steady growth as healthcare systems increasingly prioritize early diagnosis, multidisciplinary intervention, and lifelong support for individuals with autism spectrum disorder. ASD is a complex neurodevelopmental disorder characterized by challenges in social communication, repetitive behaviors, and varying levels of cognitive and behavioral functioning. The increasing prevalence of autism, improved public awareness, expanding diagnostic capabilities, and greater access to specialized healthcare services are driving sustained demand for comprehensive treatment solutions.

The market encompasses pharmacological therapies, behavioral interventions, speech and language therapy, occupational therapy, psychological counseling, educational support, digital therapeutics, telehealth services, and assistive technologies. Since no curative treatment currently exists for autism spectrum disorder, the primary objective of therapy is to improve communication skills, behavioral outcomes, adaptive functioning, social interaction, and overall quality of life. The growing adoption of individualized treatment plans and integrated care models has strengthened demand across hospitals, specialty clinics, rehabilitation centers, and community healthcare organizations.

Advances in neuroscience, genetics, artificial intelligence, digital health, and precision medicine are transforming the treatment landscape. Healthcare providers are increasingly incorporating digital behavioral assessment platforms, remote monitoring systems, teletherapy services, and personalized intervention strategies into autism management programs. These innovations are improving patient engagement, expanding treatment accessibility, and supporting long-term developmental outcomes.

The market is also benefiting from increased government initiatives, favorable reimbursement policies in several countries, expanding autism awareness campaigns, and growing investments in neurodevelopmental research. Pharmaceutical companies continue to investigate targeted therapies capable of addressing the biological mechanisms underlying ASD, while technology companies are developing innovative digital solutions to enhance behavioral intervention and patient monitoring. As healthcare infrastructure continues to improve globally, the autism spectrum disorder treatment market is expected to maintain strong growth throughout the forecast period.

Market Drivers

Increasing Prevalence of Autism Spectrum Disorder

The growing number of diagnosed autism cases is the primary factor driving market expansion. Improved screening programs, greater public awareness, and updated diagnostic criteria have increased early identification and expanded demand for treatment services.

Rising Emphasis on Early Intervention

Healthcare professionals increasingly recognize the benefits of early diagnosis and intervention in improving long-term developmental outcomes. Early behavioral therapy, speech therapy, and occupational therapy have become standard components of comprehensive autism care.

Expansion of Multidisciplinary Treatment Models

Integrated treatment approaches combining behavioral therapy, educational support, pharmacological management, rehabilitation, and psychological counseling are improving patient outcomes while increasing demand for specialized healthcare services.

Technological Advancements in Autism Care

Artificial intelligence, digital therapeutics, telehealth platforms, wearable monitoring devices, and assistive communication technologies are transforming autism treatment delivery. These innovations improve accessibility, treatment continuity, and patient engagement.

Growing Research and Healthcare Investment

Governments, pharmaceutical companies, biotechnology firms, and academic institutions continue to increase investment in autism research, therapeutic innovation, and specialized care infrastructure, supporting long-term market growth.

Market Restraints

Limited Disease-Modifying Therapies

Current pharmacological treatments primarily manage associated behavioral symptoms such as irritability, anxiety, hyperactivity, and sleep disorders rather than addressing the underlying causes of autism spectrum disorder.

High Cost of Long-Term Treatment

Individuals with ASD often require lifelong behavioral therapy, rehabilitation services, educational support, and specialized healthcare, creating significant financial burdens for families and healthcare systems.

Variability in Clinical Presentation

The broad spectrum of autism characteristics requires highly individualized treatment plans, making standardized therapeutic development and clinical outcome measurement more challenging.

Shortage of Specialized Professionals

Many healthcare systems continue to experience shortages of developmental pediatricians, behavioral therapists, speech-language pathologists, psychologists, and occupational therapists, limiting access to comprehensive autism care.

Reimbursement and Access Challenges

Variability in insurance coverage and reimbursement policies across regions continues to limit access to specialized therapies and long-term treatment programs, particularly in lower-income markets.

Technology and Segment Insights

The autism spectrum disorder treatment market can be segmented by treatment type, application, distribution channel, end user, and age group.

By Treatment Type

Behavioral therapy remains the largest treatment segment because it forms the foundation of autism management and focuses on improving communication, social interaction, learning, and adaptive behavior.

Pharmacological therapies are widely prescribed to manage associated symptoms including irritability, aggression, anxiety, attention deficits, and sleep disturbances. Antipsychotic medications continue to account for a significant share of pharmaceutical treatment, while selective serotonin reuptake inhibitors, stimulants, and sleep medications also contribute substantially to market demand.

Speech and language therapy remains essential for improving communication abilities, while occupational therapy supports sensory integration, motor coordination, and daily living skills.

Digital therapeutics, teletherapy platforms, assistive communication technologies, and artificial intelligence-enabled behavioral assessment tools represent rapidly expanding segments that are improving treatment accessibility and supporting remote patient care.

By Application

Autistic disorder accounts for the largest share of the treatment market due to its higher diagnosis rate and significant requirement for long-term multidisciplinary care.

Asperger syndrome and other autism spectrum conditions continue to contribute substantially to treatment demand as awareness and diagnostic capabilities improve across healthcare systems.

By Distribution Channel

Retail pharmacies account for a significant share of medication distribution due to the long-term pharmacological management of associated behavioral symptoms.

Hospital pharmacies support patients receiving specialized neurological and psychiatric care within healthcare facilities.

Online pharmacies continue to expand rapidly as digital healthcare adoption, electronic prescribing, and home medication delivery services become increasingly common.

By End User

Hospitals and specialty autism treatment centers remain the primary providers of diagnostic evaluation, behavioral therapy, and multidisciplinary treatment services.

Rehabilitation centers, developmental assessment clinics, educational institutions, and community healthcare organizations play critical roles in delivering long-term autism support programs.

Home-based therapy and telehealth services are becoming increasingly important as families seek flexible treatment options and broader access to specialized healthcare professionals.

By Age Group

Children represent the largest patient population due to growing emphasis on early diagnosis and early intervention programs.

Adolescents continue to require behavioral support, educational services, and psychological care during developmental transitions.

Adult autism services are expanding as healthcare systems increasingly recognize the long-term healthcare, vocational, and social support needs of adults living with autism spectrum disorder.

Competitive and Strategic Outlook

The competitive landscape includes pharmaceutical companies, biotechnology firms, behavioral healthcare providers, rehabilitation organizations, digital health companies, diagnostic technology developers, and specialized autism treatment centers. Competition is focused on expanding therapeutic portfolios, developing innovative digital health solutions, improving treatment accessibility, and delivering integrated patient-centered care.

Organizations are investing in artificial intelligence, digital therapeutics, precision medicine, wearable technologies, telehealth platforms, assistive communication systems, and biomarker research to improve diagnosis and treatment outcomes. Pharmaceutical companies continue to explore targeted therapies capable of addressing the biological pathways associated with autism spectrum disorder, while technology companies are expanding digital intervention platforms that enhance behavioral therapy delivery.

Strategic collaborations among healthcare providers, pharmaceutical companies, biotechnology developers, academic institutions, and patient advocacy organizations continue to strengthen innovation across the market. Companies capable of combining evidence-based therapeutic approaches with advanced digital technologies and personalized treatment models are expected to strengthen their competitive positions during the forecast period.

Conclusion

The global autism spectrum disorder treatment market is expected to experience sustained growth throughout the forecast period, driven by increasing autism prevalence, growing awareness, expanding early intervention programs, and continuous advances in treatment technologies. The integration of behavioral therapies, pharmacological management, digital health solutions, precision medicine, and multidisciplinary care models is transforming autism management and improving long-term patient outcomes. Although challenges related to treatment costs, workforce shortages, reimbursement limitations, and the absence of disease-modifying therapies remain, ongoing investment in neuroscience research and healthcare innovation is expected to support long-term market expansion. The autism spectrum disorder treatment market will remain a vital component of the global neurodevelopmental healthcare industry as stakeholders continue to focus on improving quality of life for individuals living with autism spectrum disorder.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
• 1.2 Emerging Therapies Landscape Overview
• 1.3 Key Findings
• 1.4 Pipeline Highlights
• 1.5 Innovation Trends
• 1.6 Key Developers and Sponsors
• 1.7 Unmet Medical Needs
• 1.8 Future Outlook

2. Autism Spectrum Disorder Overview

• 2.1 Introduction to Autism Spectrum Disorder
• 2.2 Disease Classification
  • 2.2.1 Level 1 ASD
  • 2.2.2 Level 2 ASD
  • 2.2.3 Level 3 ASD
  • 2.2.4 Syndromic Autism
  • 2.2.5 Non-Syndromic Autism
• 2.3 Disease Pathophysiology
• 2.4 Genetic and Neurobiological Basis
• 2.5 Current Standard of Care
• 2.6 Treatment Limitations
• 2.7 Unmet Clinical Needs
• 2.8 Future Therapeutic Opportunities

3. Current Treatment Landscape

• 3.1 Approved Pharmacological Treatments
• 3.2 Behavioral and Educational Interventions
• 3.3 Symptom-Based Management Approaches
• 3.4 Off-Label Treatment Practices
• 3.5 Treatment Gaps and Challenges
• 3.6 Need for Disease-Modifying Therapies

4. Emerging Therapies Landscape Analysis

• 4.1 Emerging Pipeline Overview
• 4.2 Pipeline by Development Stage
  • 4.2.1 Discovery Stage
  • 4.2.2 Preclinical Stage
  • 4.2.3 Phase I
  • 4.2.4 Phase II
  • 4.2.5 Phase III
  • 4.2.6 Registration Stage
• 4.3 Pipeline by Molecule Type
  • 4.3.1 Small Molecules
  • 4.3.2 Biologics
  • 4.3.3 Gene Therapies
  • 4.3.4 RNA-Based Therapies
  • 4.3.5 Cell Therapies
  • 4.3.6 Microbiome-Based Therapies
• 4.4 Pipeline by Route of Administration
  • 4.4.1 Oral
  • 4.4.2 Injectable
  • 4.4.3 Intranasal
  • 4.4.4 Intravenous
• 4.5 Pipeline by Target Population
  • 4.5.1 Pediatric ASD
  • 4.5.2 Adolescent ASD
  • 4.5.3 Adult ASD

5. Mechanism of Action Analysis

• 5.1 Vasopressin Receptor Modulators
• 5.2 Oxytocin Pathway Modulators
• 5.3 Glutamatergic Modulators
• 5.4 GABAergic Modulators
• 5.5 Serotonergic Modulators
• 5.6 Dopaminergic Modulators
• 5.7 Neuroinflammation Modulators
• 5.8 Synaptic Plasticity Modulators
• 5.9 Microbiome-Based Therapeutics
• 5.10 Precision Medicine Approaches
• 5.11 Novel Therapeutic Targets

6. Emerging Drug Profiles

• 6.1 Balovaptan
  • 6.1.1 Drug Overview
  • 6.1.2 Developer Profile
  • 6.1.3 Mechanism of Action
  • 6.1.4 Clinical Development History
  • 6.1.5 Clinical Trial Findings
  • 6.1.6 Regulatory Status
  • 6.1.7 Future Potential
• 6.2 L1-79
  • 6.2.1 Drug Overview
  • 6.2.2 Developer Profile
  • 6.2.3 Mechanism of Action
  • 6.2.4 Clinical Development Status
  • 6.2.5 Clinical Trial Findings
  • 6.2.6 Regulatory Status
  • 6.2.7 Future Potential
• 6.3 SB-121
  • 6.3.1 Drug Overview
  • 6.3.2 Developer Profile
  • 6.3.3 Mechanism of Action
  • 6.3.4 Clinical Development Status
  • 6.3.5 Clinical Trial Findings
  • 6.3.6 Regulatory Status
  • 6.3.7 Future Potential
• 6.4 ML-004
  • 6.4.1 Drug Overview
  • 6.4.2 Developer Profile
  • 6.4.3 Mechanism of Action
  • 6.4.4 Clinical Development Status
  • 6.4.5 Clinical Trial Findings
  • 6.4.6 Regulatory Status
  • 6.4.7 Future Potential
• 6.5 STP1
  • 6.5.1 Drug Overview
  • 6.5.2 Developer Profile
  • 6.5.3 Mechanism of Action
  • 6.5.4 Clinical Development Status
  • 6.5.5 Clinical Trial Findings
  • 6.5.6 Regulatory Status
  • 6.5.7 Future Potential
• 6.6 CM-AT
  • 6.6.1 Drug Overview
  • 6.6.2 Developer Profile
  • 6.6.3 Mechanism of Action
  • 6.6.4 Clinical Development Status
  • 6.6.5 Clinical Trial Findings
  • 6.6.6 Regulatory Status
  • 6.6.7 Future Potential
• 6.7 Intranasal Oxytocin Programs
  • 6.7.1 Drug Overview
  • 6.7.2 Developer Profile
  • 6.7.3 Mechanism of Action
  • 6.7.4 Clinical Development Status
  • 6.7.5 Clinical Trial Findings
  • 6.7.6 Regulatory Status
  • 6.7.7 Future Potential
• 6.8 Precision Medicine Candidates
  • 6.8.1 Candidate Overview
  • 6.8.2 Molecular Targets
  • 6.8.3 Development Status
  • 6.8.4 Commercial Potential

7. Clinical Development Assessment

• 7.1 Active Clinical Trials Overview
• 7.2 Completed Clinical Trials Assessment
• 7.3 Clinical Success Rate Analysis
• 7.4 Trial Design Trends
• 7.5 Patient Recruitment Trends
• 7.6 Endpoint Analysis
• 7.7 Upcoming Clinical Milestones
• 7.8 Regulatory Designations and Incentives

8. Competitive Landscape

• 8.1 Emerging Therapy Competitive Assessment
• 8.2 Pipeline Strength Benchmarking
• 8.3 Innovation Leadership Analysis
• 8.4 Mechanism-Based Competitive Assessment
• 8.5 Strategic Collaborations and Partnerships
• 8.6 Licensing Agreements
• 8.7 Investment and Financing Trends
• 8.8 Competitive Positioning Matrix

9. Market Opportunity Assessment

• 9.1 Addressable Patient Population
• 9.2 Treatment Gap Assessment
• 9.3 Commercial Opportunity Analysis
• 9.4 Adoption Potential Assessment
• 9.5 Peak Revenue Potential
• 9.6 Market Access Challenges
• 9.7 Future Commercial Outlook

10. Geographical Analysis

• 10.1 North America
  • 10.1.1 Clinical Development Activity
  • 10.1.2 Research Infrastructure
  • 10.1.3 Regulatory Environment
  • 10.1.4 Funding Trends
  • 10.1.5 Growth Opportunities
• 10.2 Europe
  • 10.2.1 Clinical Development Activity
  • 10.2.2 Research Infrastructure
  • 10.2.3 Regulatory Environment
  • 10.2.4 Funding Trends
  • 10.2.5 Growth Opportunities
• 10.3 Asia-Pacific
  • 10.3.1 Clinical Development Activity
  • 10.3.2 Research Infrastructure
  • 10.3.3 Regulatory Environment
  • 10.3.4 Funding Trends
  • 10.3.5 Growth Opportunities
• 10.4 Latin America
  • 10.4.1 Clinical Development Activity
  • 10.4.2 Research Infrastructure
  • 10.4.3 Regulatory Environment
  • 10.4.4 Funding Trends
  • 10.4.5 Growth Opportunities
• 10.5 Middle East & Africa
  • 10.5.1 Clinical Development Activity
  • 10.5.2 Research Infrastructure
  • 10.5.3 Regulatory Environment
  • 10.5.4 Funding Trends
  • 10.5.5 Growth Opportunities

11. Key Countries Analysis

• 11.1 United States
  • 11.1.1 Clinical Development Activity
  • 11.1.2 Research Infrastructure
  • 11.1.3 Regulatory Environment
  • 11.1.4 Funding Trends
  • 11.1.5 Growth Opportunities
• 11.2 Canada
  • 11.2.1 Clinical Development Activity
  • 11.2.2 Research Infrastructure
  • 11.2.3 Regulatory Environment
  • 11.2.4 Funding Trends
  • 11.2.5 Growth Opportunities
• 11.3 Germany
  • 11.3.1 Clinical Development Activity
  • 11.3.2 Research Infrastructure
  • 11.3.3 Regulatory Environment
  • 11.3.4 Funding Trends
  • 11.3.5 Growth Opportunities
• 11.4 United Kingdom
  • 11.4.1 Clinical Development Activity
  • 11.4.2 Research Infrastructure
  • 11.4.3 Regulatory Environment
  • 11.4.4 Funding Trends
  • 11.4.5 Growth Opportunities
• 11.5 France
  • 11.5.1 Clinical Development Activity
  • 11.5.2 Research Infrastructure
  • 11.5.3 Regulatory Environment
  • 11.5.4 Funding Trends
  • 11.5.5 Growth Opportunities
• 11.6 Italy
  • 11.6.1 Clinical Development Activity
  • 11.6.2 Research Infrastructure
  • 11.6.3 Regulatory Environment
  • 11.6.4 Funding Trends
  • 11.6.5 Growth Opportunities
• 11.7 Spain
  • 11.7.1 Clinical Development Activity
  • 11.7.2 Research Infrastructure
  • 11.7.3 Regulatory Environment
  • 11.7.4 Funding Trends
  • 11.7.5 Growth Opportunities
• 11.8 China
  • 11.8.1 Clinical Development Activity
  • 11.8.2 Research Infrastructure
  • 11.8.3 Regulatory Environment
  • 11.8.4 Funding Trends
  • 11.8.5 Growth Opportunities
• 11.9 Japan
  • 11.9.1 Clinical Development Activity
  • 11.9.2 Research Infrastructure
  • 11.9.3 Regulatory Environment
  • 11.9.4 Funding Trends
  • 11.9.5 Growth Opportunities
• 11.10 India
  • 11.10.1 Clinical Development Activity
  • 11.10.2 Research Infrastructure
  • 11.10.3 Regulatory Environment
  • 11.10.4 Funding Trends
  • 11.10.5 Growth Opportunities
• 11.11 South Korea
  • 11.11.1 Clinical Development Activity
  • 11.11.2 Research Infrastructure
  • 11.11.3 Regulatory Environment
  • 11.11.4 Funding Trends
  • 11.11.5 Growth Opportunities
• 11.12 Australia
  • 11.12.1 Clinical Development Activity
  • 11.12.2 Research Infrastructure
  • 11.12.3 Regulatory Environment
  • 11.12.4 Funding Trends
  • 11.12.5 Growth Opportunities

12. Company Profiles

• 12.1 Roche
  • 12.1.1 Overview
  • 12.1.2 Financials
  • 12.1.3 Autism Spectrum Disorder Emerging Therapy Portfolio
  • 12.1.4 Clinical Development Strategy
  • 12.1.5 Key Drug Candidates
  • 12.1.6 Clinical Trial Programs
  • 12.1.7 Strategic Collaborations
  • 12.1.8 Recent Developments
• 12.2 Yamo Pharmaceuticals
  • 12.2.1 Overview
  • 12.2.2 Financials
  • 12.2.3 Autism Spectrum Disorder Emerging Therapy Portfolio
  • 12.2.4 Clinical Development Strategy
  • 12.2.5 Key Drug Candidates
  • 12.2.6 Clinical Trial Programs
  • 12.2.7 Strategic Collaborations
  • 12.2.8 Recent Developments
• 12.3 Stalicla SA
  • 12.3.1 Overview
  • 12.3.2 Financials
  • 12.3.3 Autism Spectrum Disorder Emerging Therapy Portfolio
  • 12.3.4 Clinical Development Strategy
  • 12.3.5 Key Drug Candidates
  • 12.3.6 Clinical Trial Programs
  • 12.3.7 Strategic Collaborations
  • 12.3.8 Recent Developments
• 12.4 Axial Therapeutics
  • 12.4.1 Overview
  • 12.4.2 Financials
  • 12.4.3 Autism Spectrum Disorder Emerging Therapy Portfolio
  • 12.4.4 Clinical Development Strategy
  • 12.4.5 Key Drug Candidates
  • 12.4.6 Clinical Trial Programs
  • 12.4.7 Strategic Collaborations
  • 12.4.8 Recent Developments
• 12.5 SciSparc Ltd.
  • 12.5.1 Overview
  • 12.5.2 Financials
  • 12.5.3 Autism Spectrum Disorder Emerging Therapy Portfolio
  • 12.5.4 Clinical Development Strategy
  • 12.5.5 Key Drug Candidates
  • 12.5.6 Clinical Trial Programs
  • 12.5.7 Strategic Collaborations
  • 12.5.8 Recent Developments
• 12.6 Oryzon Genomics S.A.
  • 12.6.1 Overview
  • 12.6.2 Financials
  • 12.6.3 Autism Spectrum Disorder Emerging Therapy Portfolio
  • 12.6.4 Clinical Development Strategy
  • 12.6.5 Key Drug Candidates
  • 12.6.6 Clinical Trial Programs
  • 12.6.7 Strategic Collaborations
  • 12.6.8 Recent Developments
• 12.7 Curemark, LLC
  • 12.7.1 Overview
  • 12.7.2 Financials
  • 12.7.3 Autism Spectrum Disorder Emerging Therapy Portfolio
  • 12.7.4 Clinical Development Strategy
  • 12.7.5 Key Drug Candidates
  • 12.7.6 Clinical Trial Programs
  • 12.7.7 Strategic Collaborations
  • 12.7.8 Recent Developments
• 12.8 Neurochlore SAS
  • 12.8.1 Overview
  • 12.8.2 Financials
  • 12.8.3 Autism Spectrum Disorder Emerging Therapy Portfolio
  • 12.8.4 Clinical Development Strategy
  • 12.8.5 Key Drug Candidates
  • 12.8.6 Clinical Trial Programs
  • 12.8.7 Strategic Collaborations
  • 12.8.8 Recent Developments
• 12.9 Jazz Pharmaceuticals plc
  • 12.9.1 Overview
  • 12.9.2 Financials
  • 12.9.3 Autism Spectrum Disorder Emerging Therapy Portfolio
  • 12.9.4 Clinical Development Strategy
  • 12.9.5 Key Drug Candidates
  • 12.9.6 Clinical Trial Programs
  • 12.9.7 Strategic Collaborations
  • 12.9.8 Recent Developments
• 12.10 Servier
  • 12.10.1 Overview
  • 12.10.2 Financials
  • 12.10.3 Autism Spectrum Disorder Emerging Therapy Portfolio
  • 12.10.4 Clinical Development Strategy
  • 12.10.5 Key Drug Candidates
  • 12.10.6 Clinical Trial Programs
  • 12.10.7 Strategic Collaborations
  • 12.10.8 Recent Developments

13. Future Outlook and Strategic Recommendations

• 13.1 Future Therapeutic Evolution
• 13.2 Precision Medicine Outlook
• 13.3 Gene Therapy Opportunities
• 13.4 Microbiome-Based Therapy Potential
• 13.5 Partnership and Licensing Opportunities
• 13.6 Investment Trends and Opportunities
• 13.7 Long-Term Emerging Therapy Outlook (2025-2045)

14. Research Methodology

• 14.1 Primary Research
• 14.2 Secondary Research
• 14.3 Pipeline Assessment Framework
• 14.4 Emerging Therapy Evaluation Methodology
• 14.5 Forecasting Methodology
• 14.6 Data Validation and Triangulation

15. Appendix

• 15.1 Abbreviations
• 15.2 Glossary of Terms
• 15.3 References
• 15.4 List of Tables
• 15.5 List of Figures
• 15.6 Clinical Trial Sources
• 15.7 Regulatory Sources
• 15.8 Company Sources
• 15.9 Pipeline Intelligence Sources